Jubilant Pharmova Ltd. - Research Center
530019 JUBLPHARMA Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 15.90 | 15.93 | 15.93 | 15.93 | 15.93 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 2,358.60 | 2,398.62 | 1,265.89 | 1,266.52 | 2,591.37 |
| Loan funds | |||||
| Secured loans | 342.90 | 301.50 | 499.00 | 493.00 | 1,950.89 |
| Unsecured loans | - | - | - | - | - |
| Total | 2,717.40 | 2,716.05 | 1,780.82 | 1,775.45 | 4,558.18 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 995.90 | 946.47 | 148.21 | 148.93 | 2,277.53 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 284.60 | 259.07 | 24.67 | 21.85 | 412.81 |
| Net block | 711.30 | 687.40 | 123.54 | 127.08 | 1,864.72 |
| Capital work-in-progress | 37.00 | 46.97 | 0.06 | 0.33 | 59.09 |
| Investments | 1,656.90 | 1,656.57 | 1,645.75 | 1,645.98 | 1,764.03 |
| Net current assets | |||||
| Current assets, loans & advances | 586.70 | 617.54 | 60.12 | 71.20 | 1,745.55 |
| Less : current liabilities & provisions | 274.50 | 292.42 | 48.65 | 69.15 | 875.21 |
| Total net current assets | 312.20 | 325.12 | 11.47 | 2.05 | 870.34 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 2,717.40 | 2,716.05 | 1,780.82 | 1,775.45 | 4,558.18 |
| Notes: | |||||
| Book value of unquoted investments | 1,656.90 | 1,656.57 | 1,645.75 | 1,645.98 | 1,764.03 |
| Market value of quoted investments | - | - | - | - | - |
| Contingent liabilities | 92.00 | 116.26 | 69.70 | 70.39 | 478.39 |
| Number of equity sharesoutstanding (Lacs) | 1592.81 | 1592.81 | 1592.81 | 1592.81 | 1592.81 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis